The developers, Pfizer and BioNTech describe it as “great day for science and humanity”.
Their vaccine has tested in 43,500 people in six countries/regions and has not caused safety risks.
These companies plan to apply for emergency approval to use the vaccine before the end of the month.
There are still huge challenges in the future. However, this statement has warmly welcomed by scientists. They called themselves smiling “ear to ear” and said that by spring, life may return to normal.
Sir John Bell, Professor of Medicine at the University of Oxford Regis University, said:
“I am probably the first guy to say that, but I will say that with some confidence.”
Vaccines and better treatments are assume as the best way to get rid of the constraints imposed on our lives.
The final stage of the test has about a dozen stages-called a Phase 3 trial-but this is the first stage to show any results.
It uses a completely experimental method-including injecting part of the virus’ genetic code-to train the immune system.
Previous tests have shown that this vaccine can train the body to make two antibodies-and another part of the immune system, called T cells, to fight the coronavirus.
Two doses are required, three weeks apart. Tests in the United States, Germany, Brazil, Argentina, South Africa and Turkey have shown that 90% of the protective effect is achieved 7 days after the second dose.
Pfizer believes that by the end of this year, it will be able to provide 50 million doses, and by the end of 2021, it will provide about 1.3 billion doses.
By the end of this year, the UK should have received 10 million doses, and another 30 million doses have already been ordered.
However, there are logistical challenges because vaccines must be stored at low temperatures below 80 degrees Celsius.
When will the pandemic end?
So far, achieving such an amazing achievement is an amazing feat.
In such a short period of time, no vaccine can prove effective from the drawing board.
And this vaccine seems to be more effective than people hope.
There are still some questions-how long does the immunization last, does the vaccine work in high-risk elderly, does it prevent you from spreading the virus or just cause the symptoms to develop?
The journey ahead is long and complicated for a healthy life.
It is a huge challenge to produce enough doses and then actually vaccinate hundreds of millions of people around the world.
Staff in hospitals and nursing homes, as well as those at the highest risk of Covid-19, will be given priority.
Therefore, in the future, masks and social distance are likely to become features of our lives.
But in the end, the Covid haze began to give way, hopefully it will end one day.
Dr. Albert Burla, Chairman of Pfizer, said:
“We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.”
Professor Ugur Sahin, one of the founders of BioNTech, described the result as a “milestone.”
The data provided is not the final analysis. It is based on the first 94 volunteers who developed Covid-the exact effectiveness of the vaccine may change after analyzing all the results.
Pfizer and BioNTech said they will obtain sufficient safety data by the third week of November to hand over their vaccine to regulators. Before that, it is impossible for countries to start their vaccination campaigns.
However, the company’s announcement received a major development and was welcomed.
Professor Peter Hobby of Oxford University said: “This news made me smile from ear to ear.”
“It is a relief… there is a long long way to go before vaccines will start to make a real difference, but this feels to me like a watershed moment.”
The official spokesperson of the British Prime Minister said that the results are “promising”,
“The NHS stands ready to begin a vaccination programme for those most at risk once a Covid-19 vaccine is available”.